Back to top

Image: Bigstock

Dynavax Technologies (DVAX) Jumps: Stock Rises 6.6%

Read MoreHide Full Article

Dynavax Technologies Corporation (DVAX - Free Report) was a big mover last session, as the company saw its shares rise nearly 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $4.84 –$7.92 in the past one-month time frame, witnessed a sharp increase on Friday.

This move came after the company announced that it has dosed the first participants in Clover Biopharmaceuticals’ vaccine study for coronavirus.

The company have seen two positive estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few months, suggesting that more solid trading could be ahead for Dynavax Technologies. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Dynavax Technologies Corporation Price

Dynavax Technologies currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

A better-ranked stock in the Medical – Biomedical and Genetics industry is Akcea Therapeutics, Inc (AKCA - Free Report) , which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks Top 10 Stocks for 2020

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?

Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.

Access Zacks Top 10 Stocks for 2020 today >>


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Dynavax Technologies Corporation (DVAX) - free report >>

Akcea Therapeutics, Inc. (AKCA) - free report >>